Lack of resources and staff are two of the main reasons why FDA does not conduct more overseas pre-approval and post-market inspections, Deborah Autor, director of FDA's Center for Drug Evaluation's Office of Compliance, told generic drug makers meeting in Bethesda, Md.

Link to Article

Pharmasianews.com